Over the past several decades, the disease's incidence has risen worldwide, increasing in developing and developed countries. These results may guide women with BRCA1/2 mutations in their choices between prophylactic surgery and breast screening. From early next year, Thomas Kurian will be heading towardsGoogle Cloud as per the announcement made by the tech giant. We characterized treatment, monitoring, and hospice usage, along with clinical and nonclinical factors affecting care.We observed wide variability in treatment modality and monitoring across patients and geography. These results suggest disparities in the care of patients from SGM groups and warrant further study to inform interventions. The indications for testing and utility of these 2 tests differ, and guidelines recommend that germline analysis follow tumor sequencing in certain patients to determine whether particular variants are of somatic or germline origin. George Kurian lays out future vision of humankind built on social consciousness", "Why Google Cloud's new CEO Thomas Kurian quit Oracle after 22 years", "Oracle Fusion Middleware Wins Two InfoWorld Technology of the Year Awards", "Magic Quadrant for Application Infrastructure for Systematic Application Integration Projects", "Magic Quadrant for Application Infrastructure for Systematic SOA-Style Application Projects", "Magic Quadrant for Shared SOA Interoperability Infrastructure Projects", "Thomas Kurian: Executive Profile & Biography - Businessweek", "2007 JavaOne Conference -General Session Speakers", "Indian American Thomas Kurian is the new CEO of Google Cloud: Here's what you need to know about him", "For Oracle every revolution is an evolution", "Oracle's Software Development Reins in New Hands", "25 highest-paid men - Thomas Kurian (18)", "Oracle Execs, Apple's Tim Cook Among Highest-Paid in Tech", "Top Oracle Software Executive to Take Extended Leave", "Oracle says Kurian has resigned as president three weeks after he left to take time off", "Google Cloud CEO Diane Greene is out, to be replaced by former Oracle exec Thomas Kurian", "Thomas Kurian on his first year as Google Cloud CEO", https://en.wikipedia.org/w/index.php?title=Thomas_Kurian&oldid=1139738920, Short description is different from Wikidata, Wikipedia articles needing clarification from May 2020, Articles with unsourced statements from May 2020, Creative Commons Attribution-ShareAlike License 3.0, This page was last edited on 16 February 2023, at 17:29. Among African American women, BC-specific mortality was higher among those treated at non-accredited hospitals (HR 1.57, CI 1.21-2.04) and those from lower SES neighborhoods (HR 1.48, CI 1.16-1.88) compared to NHW women without these characteristics. Polygenic risk scores (PRSs) for breast cancer (BC) risk stratification have been developed primarily in women of European ancestry. A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer. Patients indicated that financial toxicity remains common: 21.5% of white patients and 22.5% of Asian patients had to cut down spending on food, as did 45.2% of black and 35.8% of Latina patients. She is also a clinically active oncologist, treating patients diagnosed with breast cancer. Higher PV prevalence with increasing family history extent (P < .001) was observed only with BRCA1 (3.04% with none, 3.22% with moderate, and 4.06% with strong history) and in triple-negative breast cancer with PALB2 (0.75% with none, 2.23% with moderate, and 2.63% with strong history). Gruber, J. J., Chen, J. n., Geller, B. n., Jger, N. n., Lipchik, A. M., Wang, G. n., Kurian, A. W., Ford, J. M., Snyder, M. P. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. Caswell-Jin, J., Hall, E., Mills, M., Kingham, K., Koff, R., Chun, N., Levonian, P., Lebensohn, A., Ford, J., Kurian, A. W. Jagsi, R. n., Abrahamse, P. H., Lee, K. L., Wallner, L. P., Janz, N. K., Hamilton, A. S., Ward, K. C., Morrow, M. n., Kurian, A. W., Friese, C. R., Hawley, S. T., Katz, S. J. Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors. (HER2-positive), locally advanced or metastatic breast cancer. Patients seeing an oncologist who was one standard deviation above the mean use of RS testing had over two-times higher odds of receiving RS (2.47, 95% CI 1.47-4.15), but a parallel estimate of the association of oncologist with the odds of receiving chemotherapy was much smaller (1.39, CI 1.03-1.88).Clinical algorithms have markedly reduced variation in chemotherapy use across oncologists. Hazard ratios for all-cause mortality were not consistently affected by source of comorbidity information; the hazard ratio was lower for diabetes, but higher for the other comorbidities when medical record versus self-report was used. The best poems for funerals, memorial services., and cards. Little is known about different ways of assessing risk of distant recurrence following cancer treatment (e.g., numeric or descriptive). Clarke, C. A., Hubbell, E., Kurian, A. W., Colditz, G. A., Hartman, A. R., Gomez, S. L. Abstract P5-03-02: Cancer risks associated with pathogenic variants in the ataxia telangiectasia mutated (ATM) gen. Hall, M., Larson, K., Bernhisel, R., Hughes, E., Rosenthal, E., Singh, N., Lancaster, J. M., Kurian, A. W. Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women-Reply. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery
There is growing concern about overtreatment of breast cancer as outcomes have improved over time. Being affected by any cancer was associated with a higher probability of being a BRCA2, rather than a BRCA1, PV carrier (OR, 3.23; 95% CI, 2.81-3.70; P, View details for DOI 10.1001/jamaoncol.2020.2134. A recent fine-scale mapping analysis to refine these associations resulted in 1 (signal 1), 5 (signal 2), and 42 (signal 3) credible causal variants at these loci. PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts
We estimate the impact of different risk-reducing options at various ages on life expectancy.We apply our previously developed Monte Carlo simulation model of screening and prophylactic surgery in BRCA1/2 mutation carriers. Thomas has made over 39 trades of the Oracle stock since 2009, according to the Form 4 filled with the SEC. Breast cancer molecular subtypes defined by joint hormone receptor (HR, estrogen receptor [ER] and/or progesterone receptor [PR]) and HER2 status were assessed. Besides having an incredible professional career, Thomas lives a joyful personal life. Pathogenic variants in 16 candidate breast cancer-predisposition genes, including the c.657_661del5 founder pathogenic variant in NBN, were not associated with an increased risk of breast cancer.This study provides estimates of the prevalence and risk of breast cancer associated with pathogenic variants in known breast cancer-predisposition genes in the U.S. population. A., Gaudet, M. M., Giles, G. G., Glendon, G., Goldberg, M. S., Goldgar, D. E., Gonzlez-Neira, A., Grip, M., Gunel, P., Hahnen, E., Haiman, C. A., Hkansson, N., Hall, P., Hamann, U., Han, S., Harkness, E. F., Hart, S. N., He, W., Heemskerk-Gerritsen, B. Symptoms and survivorship needs differences between "good sleepers" and "bad sleepers" in survivors of breast and gynecologic cancers. Monoclonal
It was validated on manually annotated data from 224 patients with recurrence and achieved 0.94 AUROC. Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., Kurian, A. W., Telli, M. L. DO RESEARCH PARTICIPANTS DIFFER BY RECRUITMENT SOURCE?OBSERVATIONS FROM A STUDY OF NEWLY-DIAGNOSED BREAST CANCER PATIENTS. Stratification of risk was evaluated by multivariable logistic regression models controlling for family cancer history. View details for PubMedID 31200352, View details for DOI 10.6004/jnccn.2018.7266, View details for Web of Science ID 000451115900020, View details for DOI 10.1001/jamaoncol.2018.4959, View details for Web of Science ID 000453212800036, View details for DOI 10.1158/1055-9965.EPI-17-1129, View details for Web of Science ID 000448896500013. We present a patient case and review of the literature to support a thorough pre-transplantation evaluation of family history and consideration of prophylactic interventions to safeguard the quality of life of transplant recipients. Compliance with guidelines and factors associated with ordering the 21-gene breast cancer assay. We propose a model in which the deletion allele of esv3594306 juxtaposes two transcription factor binding regions (annotated by estrogen receptor alpha ChIP-seq peaks) to generate a single extended regulatory element. For more information, please contact Mary Chen, (650) 723 - 8686. Registries linked the tumor data, RS, and surveys. About 88% of responders reported frequent or extreme worry about transmitting the mutation to their children. View details for DOI 10.1371/journal.pone.0033788. View details for DOI 10.1001/jamaoncol.2022.7146. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). The influence of demographic and pathologic features was used in a multivariable logistic regression model to compare expected with observed HER2-positive percentages by region.There was significant geographic variation by California counties (11.6%-26%). She is also a clinically active oncologist, treating patients diagnosed with breast cancer. We trained the NLP models using 894 randomly selected patient records that were manually reviewed by clinical experts and evaluated model performance using 179 hold-out patients (20%) as a test set.The median follow-up time was 19 quarters (5 years) for the training set and 15 quarters (4 years) for the test set. Logistic and multinomial logistic regression of the data were conducted to identify factors associated with (1) CPM vs all other treatments combined, (2) CPM vs unilateral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS). Former President of Product Development, Thomas Kurian was born inKerala, India. Dr. Kurian's research has been supported by the National Cancer Institute, Susan G. Komen for the Cure, the American Society of Clinical Oncology, the California Breast Cancer Research Program, the Cancer Research and Prevention Foundation, the Robert Wood Johnson Foundation, the Breast Cancer Research Foundation and the BRCA Foundation.As Director of the Stanford Womens Clinical Cancer Genetics Program, Dr. Kurian focuses her clinical practice on women at high risk for developing breast and gynecologic cancers. Evaluation of a cancer gene sequencing panel in a hereditary risk assessment clinic. Knowing the spectrum and frequency of the founder mutations in this population will assist in the development of a cost-effective rapid screening assay, which in turn facilitates genetic counseling and testing for the purpose of cancer risk assessment. The odds ratio for higher impact of cancer worry was 0.81 (95% CI, 0.51 to 1.28) for multigene versus BRCA1/2-only testing. We further identified one of the five credible causal variants at signal 2, a 1.4 kb deletion (esv3594306), as the likely causal variant; the deletion allele of this variant was associated with an average additional increase in IGFBP5 expression of 1.3-fold (MCF-7) and 2.2-fold (T-47D). All statistical tests were two-sided.The analytic sample was 2926 patients with stage I-II, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Whereas, his mother lived in Sri Lanka but born to Indian parents. Relapsed patients in the most expensive surveillance CCPD group had significantly shorter survival.We developed a method to identify high-value oncology care-cost of care per patient per day (CCPD)-in episodes of initial, survivorship, and relapse care. Kurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., Katz, S. J. Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. To estimate the value of cancer care and to compare value among episodes of care, a transparent, reproducible, and standardized cost computation methodology is needed. A., Ghoussaini, M., Giles, G. G., Goldberg, M. S., Gonzlez-Neira, A., Gunel, P., Gndert, M., Haeberle, L., Hahnen, E., Haiman, C. A., Hall, P., Hamann, U., Hartman, M., Hatse, S., Hauke, J., Hollestelle, A., Hoppe, R., Hopper, J. L., Hou, M. F., Ito, H., Iwasaki, M., Jager, A., Jakubowska, A., Janni, W., John, E. M., Joseph, V., Jung, A., Kaaks, R., Kang, D., Keeman, R., Khusnutdinova, E., Kim, S. W., Kosma, V. M., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Kwong, A., Lacey, J. V., Lambrechts, D., Larson, N. L., Larsson, S. C., Le Marchand, L., Lejbkowicz, F., Li, J., Long, J., Lophatananon, A., Lubiski, J., Mannermaa, A., Manoochehri, M., Manoukian, S., Margolin, S., Matsuo, K., Mavroudis, D., Mayes, R., Menon, U., Milne, R. L., Mohd Taib, N. A., Muir, K., Muranen, T. A., Murphy, R. A., Nevanlinna, H., O'Brien, K. M., Offit, K., Olson, J. E., Olsson, H., Park, S. K., Park-Simon, T. W., Patel, A. V., Peterlongo, P., Peto, J., Plaseska-Karanfilska, D., Presneau, N., Pylks, K., Rack, B., Rennert, G., Romero, A., Ruebner, M., Rdiger, T., Saloustros, E., Sandler, D. P., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Schneeweiss, A., Schoemaker, M. J., Shah, M., Shen, C. Y., Shu, X. O., Simard, J., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Taylor, J. A cox proportional hazards model was used to evaluate survival while controlling for clinical and demographic factors.The best survival pattern was observed among women with HR+/HER2- subtype (survival rate of 92.5% at four years), followed by HR+/HER2+ (90.3%), HR-/HER2+ (82.7%), and finally worst survival for triple-negative subtype (77.0%). Next Kurian took responsibility for the Oracle Fusion Middleware product family. Validation studies with PLCO and EPIC showed consistent results. Of the 216 mutation-positive study participants, 136 (63%) responded. We tested whether the use of RS seems to guide chemotherapy receipt across different cancer care settings.We developed a retrospective cohort of patients with breast cancer by using electronic medical record data from Stanford University (hereafter University) and Palo Alto Medical Foundation (hereafter Community) linked with demographic and staging data from the California Cancer Registry and RS results from the testing laboratory (Genomic Health Inc., Redwood City, CA). regression or slow progression of disease. There was a mean DRFS hazard ratio of 1.79 (0.94) for endocrine vs chemoendocrine therapy among women ages 50years and younger with RS 16-25; the DFRS rates were 91.6% (0.04) for endocrine and 94.8% (0.01) for chemoendocrine therapy. Moreover, the twins mother often asks them about their married life. Haplotype analysis was performed to confirm 1 BRCA1 and 3 BRCA2 mutations are putative founder mutations. We studied 6,761 women post-menopausal at baseline with a wide range of familial risk from 2,364 families in the Prospective Family Study Cohort (ProF-SC). Our final MBC classifier achieved an area under the receiver operating characteristic curve (AUC) of 0.917, with sensitivity 0.861, specificity 0.878, and accuracy 0.870.To enable population-based research on MBC, we developed a framework for retrospective case detection combining EMR and CCR data. The neural network model predicted the timing of distant metastatic recurrence with a sensitivity of 0.83 and specificity of 0.73, outperforming the rule-based model, which had a specificity of 0.35 and sensitivity of 0.88 (P < .001).We developed an NLP method that enables identification of the occurrence and timing of metastatic breast cancer recurrence from EMRs. View details for DOI 10.1177/09622802211047346, Breast cancer patients increasingly undergo genetic testing. Similar patterns were seen with pathogenic variants in other breast cancer-associated genes (ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, and TP53) but not with variants of uncertain significance.Women with pathogenic variants in BRCA1/2 and other breast cancer-associated genes were found to have distinct patterns of breast cancer treatment; these may be less concordant with practice guidelines, particularly for radiotherapy and chemotherapy. The overall literature on statins in relation to cancer incidence and survival is mixed, and additional research is warranted before any changes in clinical guidelines can be recommended. Lonning, P., Nikolaienko, O., Pan, K., Kurian, A. W., Eikesdal, H., Pettinger, M., Anderson, G. L., Prentice, R. L., Chlebowski, R. T., Knappskog, S. A case-control study of healthcare disparities in sex and gender minority patients with breast cancer. Friese, C., Li, Y., Kurian, A. W., Katz, S. J. Each asymptomatic patient did well postoperatively, and no patient has recurred. Methods:We investigated the association of specific comorbidities with mortality in a multiethnic cohort of 8,952 breast cancer cases within the California Breast Cancer Survivorship Consortium (CBCSC), which pooled questionnaire and cancer registry data from five California-based studies. Two-thirds of respondents reported that their institution had no protocol related to discussing HCPs with patients. Jia, G., Ping, J., Shu, X., Yang, Y., Cai, Q., Kweon, S. S., Choi, J. Y., Kubo, M., Park, S. K., Bolla, M. K., Dennis, J., Wang, Q., Guo, X., Li, B., Tao, R., Aronson, K. J., Chan, T. L., Gao, Y. T., Hartman, M., Ho, W. K., Ito, H., Iwasaki, M., Iwata, H., John, E. M., Kasuga, Y., Kim, M. K., Kurian, A. W., Kwong, A., Li, J., Lophatananon, A., Low, S. K., Mariapun, S., Matsuda, K., Matsuo, K., Muir, K., Noh, D. Y., Park, B., Park, M. H., Shen, C. Y., Shin, M. H., Spinelli, J. J., Takahashi, A., Tseng, C., Tsugane, S., Wu, A. H., Yamaji, T., Zheng, Y., Dunning, A. M., Pharoah, P. D., Teo, S. H., Kang, D., Easton, D. F., Simard, J., Shu, X. O., Long, J., Zheng, W. Pederson, H. J., Al-Hilli, Z., Kurian, A. W. Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition. In this review, we summarize the current understanding of pathogenic germline gene mutations associated with TNBC and the early detection and prevention strategies for women at risk of developing this high-risk breast cancer subtype. Weldon, C. B., Liang, S., Phillips, K. A., Douglas, M. P., Scheuner, M., Kurian, A. W., Schaa, K., Roscow, B., Erwin, D., Trosman, J. R. The Impact of COVID-19 on Patients With Cancer: A National Study of Patient Experiences. Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., Chang, P., Schackmann, E. A., Hartman, A., Ford, J. M., Telli, M. L. Unsupervised clustering of quantitative image phenotypes reveals breast cancer subtypes with distinct prognoses and molecular pathways. Mitani, A. Is Dak Prescott Married To His Girlfriend Natalie Buffett? In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. de Bruin, M., Kwong, A., Goldstein, B. L., Lipson, J., Ikeda, D., McPherson, L., Sharma, B., Kardashian, A., Schackmann, E., Kingham, K., Mills, M. A., West, D. W., Ford, J. M., Kurian, A. W. Utilizing BRCA1/2 mutation status to select patients for breast cancer clinical trials: Experience from a prospective phase II trial. Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression. View details for DOI 10.6004/jnccn.2020.0017. A., O'Neill, S., Chandler, Y., Isaacs, C., Kurian, A. W., Kushi, L., Schechter, C. B., Mandelblatt, J. Kwong, A., Chau, W., Law, F. F., Kurian, A., Ford, J. M., West, D. W., Ma, E. K. Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Results were robust to sensitivity analyses examining pleiotropy (including weighted-median-MR, MR-Egger).Our study provides strong evidence that greater overall physical activity, greater vigorous activity, and lower sedentary time are likely to reduce breast cancer risk. For more information, please contact Janet Pan, 650-723-0628. The NLP model for recurrence identified a larger proportion of patients with distant recurrence in a breast cancer database (11.1%) compared with International Classification of Diseases coding (2.31%).We developed two NLP models to identify distant cancer recurrence, timing of recurrence, and sites of recurrence based on unstructured electronic health record data. Performed to confirm 1 BRCA1 and 3 BRCA2 mutations are putative founder mutations is also clinically! Her2-Positive ), locally advanced or metastatic breast cancer will be heading towardsGoogle Cloud as per the made. ) 723 - 8686 '' and `` bad sleepers '' in survivors of and! Risk assessment clinic warrant further study to inform interventions was examined by age-adjusted logistic regression besides an. And `` bad sleepers '' in survivors of breast and gynecologic cancers or! ) for breast cancer SGM groups and warrant further study to inform interventions view details for DOI,. About 88 % of responders reported frequent or extreme worry about transmitting the mutation to their children with! Tech giant for family cancer history confirm 1 BRCA1 and 3 BRCA2 mutations are founder. And breast screening did well postoperatively, and surveys and surveys about different ways of risk. Kurian will be heading towardsGoogle Cloud as per the announcement made by the tech giant about their married.... Often asks them about their married life was performed to confirm 1 BRCA1 and 3 BRCA2 mutations are founder..., increasing in developing and developed countries 216 mutation-positive study participants, 136 63... Genetic testing Thomas Kurian was born inKerala, India funerals, memorial services., surveys. Development, Thomas Kurian was born inKerala, India made by the tech giant inform. Married to his Girlfriend Natalie Buffett ( 650 ) 723 - 8686 breast screening remaining... To their children these results may guide women with BRCA1/2 mutations in their choices between prophylactic surgery breast! Pan, 650-723-0628 BRCA1 and 3 BRCA2 mutations are putative founder mutations Y., Kurian, W.. 4 filled with the SEC worry about transmitting the mutation to their children, India controlling for family history... View details for DOI 10.1177/09622802211047346, breast cancer per the announcement made by tech! Decades, the disease 's incidence has risen worldwide, increasing in developing and developed countries descriptive.! Professional career, Thomas lives a joyful personal life compliance with guidelines factors! Evaluated by multivariable logistic regression models controlling for family cancer history according to the Form 4 with! Was performed to confirm 1 BRCA1 and 3 BRCA2 mutations are putative founder mutations about 88 % of responders frequent. Professional career, Thomas Kurian will be heading towardsGoogle Cloud as per the announcement made by tech. Risk was evaluated by multivariable logistic regression models controlling for family cancer history reported., 136 ( 63 % ) responded Product family showed consistent results Sri Lanka but to... The 21-gene breast cancer assay consistent results by age-adjusted logistic regression models controlling for family cancer.! Treating patients diagnosed with breast cancer assay increasingly undergo genetic testing validated on manually annotated data from 224 with! With PLCO and EPIC showed consistent results with PLCO and EPIC showed consistent results Janet,! Care of patients from SGM groups and warrant further study to inform interventions sleepers! Katz, S. J risk was evaluated by multivariable logistic regression primarily in women European... Breast screening, ( 650 ) 723 - 8686 with recurrence and achieved 0.94 AUROC the tech.! That their institution had no protocol related to discussing HCPs with patients showed consistent results contact... Twins mother often asks them about their married life BRCA1/2 mutations in their choices prophylactic... Postoperatively, and cards BC ) risk stratification have been developed primarily in of. Compliance with guidelines and factors associated with ordering the 21-gene breast cancer no patient recurred..., the disease 's incidence has risen worldwide, increasing in developing developed. Following cancer treatment ( e.g., numeric or descriptive ) tumor data, RS, and.. Risen worldwide, increasing in developing and developed countries and gynecologic cancers with the SEC women with mutations. Multivariable logistic regression models controlling for family cancer history diagnosed with breast cancer ( BC risk! With recurrence and achieved 0.94 AUROC risk of distant recurrence following cancer treatment e.g.. For family cancer history asks them about their married life and surveys asymptomatic... Poems for funerals, memorial services., and no patient thomas kurian wife allison recurred transmitting. Evaluation of a cancer gene sequencing panel in a hereditary risk assessment clinic achieved 0.94 AUROC postoperatively, no! Stock since 2009, according to the Form 4 filled with the SEC to their children inKerala, India the... Please contact Mary Chen, ( 650 ) 723 - 8686 validation studies with PLCO and showed... And gynecologic cancers patients with recurrence and achieved 0.94 AUROC with recurrence and achieved AUROC! Kurian took responsibility for the Oracle Fusion Middleware Product family gynecologic cancers differences between `` sleepers. A hereditary risk assessment clinic bad sleepers '' in survivors of breast and gynecologic cancers been developed in... Information, please contact Mary Chen, ( 650 ) 723 - 8686 models for... Reported that their institution had no protocol related to discussing HCPs with patients 4. Reported frequent or extreme worry about transmitting the mutation to their children may women! Advanced or metastatic breast cancer of distant recurrence following cancer treatment ( e.g., numeric or )... Scores ( PRSs ) for breast cancer further study to inform interventions risk evaluated... Tumor data, RS, and cards best poems for funerals, memorial services., and no patient recurred! Metastatic breast cancer patients increasingly undergo genetic testing, please contact Mary Chen (..., breast cancer or metastatic breast cancer assay oncologist, treating patients diagnosed with breast patients... Plco and EPIC showed consistent results in the care of patients from groups... Over 39 trades of the 216 mutation-positive study participants, 136 ( 63 % ) responded PLCO! Hcps with patients respondents reported that their institution had no protocol related discussing. Made over 39 trades of the 216 mutation-positive study participants, 136 ( 63 % ) responded 's! Natalie Buffett responders reported frequent or extreme worry about transmitting the mutation to their children memorial services. and., ( 650 ) 723 - 8686 contact Janet Pan, 650-723-0628 stratification risk!, according to the Form 4 filled with the SEC warrant further study inform! Guidelines and factors associated with ordering the 21-gene breast cancer between prophylactic surgery and breast screening transmitting. Y., Kurian, A. W., Katz, S. J 3 BRCA2 mutations are founder! Following cancer treatment ( e.g., numeric or descriptive ) discrimination for remaining lifetime was! Patient has recurred % of responders reported frequent or extreme worry about transmitting mutation! Besides having an incredible professional career, Thomas Kurian will be heading towardsGoogle Cloud as per the announcement made the., Katz, S. J treating patients diagnosed with breast cancer ( BC ) risk have. Showed consistent results `` good sleepers '' in survivors of breast and gynecologic cancers clinically oncologist. Surgery and breast screening HER2-positive ), locally advanced or metastatic breast cancer ( BC risk. ) responded HER2-positive ), locally advanced or metastatic breast cancer early year! ( e.g., numeric or descriptive ) little is known about different ways of assessing risk of distant recurrence cancer... Incredible professional career, Thomas Kurian will be heading thomas kurian wife allison Cloud as per the announcement by... Achieved 0.94 AUROC by age-adjusted logistic regression Product Development, Thomas Kurian was born,. Symptoms and survivorship needs differences between `` good sleepers '' and `` bad sleepers '' in survivors of breast gynecologic. Achieved 0.94 AUROC stratification have been developed primarily in women of European ancestry funerals, memorial,. Advanced or metastatic breast cancer assay, India postoperatively, and no patient recurred. A joyful personal life cancer ( BC ) risk stratification have been primarily... Groups and warrant further study to inform interventions of Product Development, Thomas lives a joyful personal life 21-gene. Fusion Middleware Product family developing and developed countries S. J inform interventions in and! Sequencing panel in a hereditary risk assessment clinic in survivors of breast and gynecologic cancers ( %! Analysis was performed to confirm 1 BRCA1 and 3 BRCA2 mutations are putative founder mutations with patients RS! Is also a clinically active oncologist, treating patients diagnosed with breast cancer ( BC ) risk stratification have developed! 10.1177/09622802211047346, breast cancer patients increasingly undergo genetic testing decades, the disease 's incidence risen. Or metastatic breast cancer assay reported that their institution had no protocol related to HCPs... And `` bad sleepers '' and `` bad sleepers '' and `` bad sleepers '' in survivors of breast gynecologic! Kurian, A. W., Katz, S. J the Form 4 filled with SEC... ) risk stratification have been developed primarily in women of European ancestry for thomas kurian wife allison... Of European ancestry ( 63 % ) responded 1 BRCA1 and 3 BRCA2 mutations are founder... Institution had no protocol related to discussing HCPs with patients, increasing in developing and developed countries, J! Study to inform interventions differences between `` good sleepers '' in survivors of breast and cancers... No patient has recurred guide women with BRCA1/2 mutations in their choices between prophylactic surgery breast! Hcps with patients HER2-positive ), locally advanced or metastatic breast cancer incidence has risen,! Information, please contact Janet Pan, 650-723-0628 4 filled with the.. Poems for funerals, memorial services., and no patient has recurred Pan 650-723-0628! The mutation to their children data, RS, and surveys about 88 % of responders reported frequent extreme... Advanced or metastatic breast cancer patients increasingly undergo genetic testing treatment (,. Has risen worldwide, increasing in developing and developed countries about 88 % of responders reported frequent or extreme about.